Treadwell Therapeutics, Inc.
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
- Conditions
- Advanced Solid TumorBreast Cancer
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Treadwell Therapeutics, Inc
- Target Recruit Count
- 44
- Registration Number
- NCT05251714
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START - Mountain Region, West Valley City, Utah, United States
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
- Conditions
- AMLMDSMyelodysplastic SyndromesCMMLAcute Myeloid LeukemiaChronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Treadwell Therapeutics, Inc
- Target Recruit Count
- 72
- Registration Number
- NCT04730258
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Norton Cancer Institute - Saint Matthews, Louisville, Kentucky, United States
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
- Conditions
- Advanced Solid Malignancies
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Treadwell Therapeutics, Inc
- Target Recruit Count
- 170
- Registration Number
- NCT04521413
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸The Angeles Clinic, Los Angeles, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States